Precision medicine for severe asthma – Biological targeted therapy

• DOI: 10.1016/j.intimp.2024.112189
• Publication Date: 2024-05-16T22:47:13Z
• Authors: Bingqing Sun; Kunlu Shen; Ruiheng Zhao; Yun Li; Min Xiang; Jiangtao Lin
• Keywords: Thymic stromal lymphopoietin; Omalizumab; Personalized Medicine; Benralizumab

Severe asthma is a complex and heterogeneous chronic airway inflammatory disease. Current treatment strategies are increasingly focused on disease classification, facilitating the transition towards personalized medicine by integrating biomarkers monoclonal antibodies for tailored therapeutic approaches. Several approved biological agents, including anti-immunoglobulin E (IgE), anti-interleukin (IL)-4, anti-IL-5, anti-thymic stromal lymphopoietin (TSLP) antibodies, have demonstrated significant efficacy in reducing exacerbations, eosinophil counts, improving lung function, minimizing oral corticosteroid usage, enhancing patients' quality of life. The utilization these agents has brought about profound transformations management severe asthma. This article provides comprehensive review while emphasizing increasing importance further research into its pathogenesis novel modalities.